Previous 10 | Next 10 |
PRA Health Sciences (PRAH): Q4 Non-GAAP EPS of $1.55 beats by $0.09; GAAP EPS of $0.78 misses by $0.33.Revenue of $873.46M (+9.1% Y/Y) beats by $45.79M.Press Release For further details see: PRA Health Sciences EPS beats by $0.09, beats on revenue
Net new business of $872.4 million in the fourth quarter excluding reimbursement revenue; representing growth of 32.4%; Net book-to-bill of 1.42 Net new business of $1,437.8 million in the fourth quarter including reimbursement revenue; representing growth of 58.4%; Net boo...
The consolidation brings together two organizations with a history of robust growth and performance ready to build on this strength using the outstanding talent of both companies to deliver enhanced value to patients, customers, employees and shareholders. All cust...
PPD went public in February 2020, raising $1.6 billion in gross proceeds in a U.S. IPO. The firm provides contract research services to biopharmaceutical and research organizations worldwide. While Q3 saw strong growth from its COVID-19 study work, I believe the virus and its vari...
RALEIGH, N.C., Feb. 04, 2021 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) will release its fourth quarter and full year 2020 results after the market closes on Thursday, February 25, 2021. The Company will also host a conference call on Friday, February 26, 2021 at 9:00...
Fulgent's core genetic testing business is recovering and should improve even further due to synergies with the COVID-19 business. Many people thought COVID-19 would dissipate in 2021 as the vaccine is rolled out, but delays in administration of the vaccine mean that testing will cont...
RALEIGH, N.C., Dec. 17, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences (NASDAQ: PRAH) announced today the enhancement of its COVID-19 Monitoring Program with the addition of at-home COVID-19 testing capabilities. Enabled through a collaboration with PWNHealth and Fulgent Genetics (NASDAQ: FLG...
Glenview Capital Management’s 13F portfolio value decreased from $3.63B to $3.19B this quarter. The number of positions increased from 43 to 45. They increased Myriad Genetics, while decreasing Quest Diagnostics, DaVita, and United Rentals during the quarter. The top three ...
RALEIGH, N.C. , Nov. 19, 2020 (GLOBE NEWSWIRE) -- PRA Health Sciences, Inc. (NASDAQ: PRAH) announced today the appointment of Isaac Rodriguez-Chavez, PhD, MHS, MS, as Senior Vice President, Scientific and Clinical Affairs. He will lead the company’s Global Center of Excellence for De...
A dashboard with metrics in healthcare industries. Value and quality scores, and their evolution since last month. A list of cheap stocks. For further details see: XLV: Healthcare Dashboard For November
News, Short Squeeze, Breakout and More Instantly...
PRA Health Sciences Inc. Company Name:
PRAH Stock Symbol:
NASDAQ Market:
PRA Health Sciences Inc. Website:
DT Midstream Set to Join S&P MidCap 400 DT Midstream Set to Join S&P MidCap 400 PR Newswire NEW YORK , June 28, 2021 /PRNewswire/ -- DT Midstream Inc. (NYSE: DTM) will replace PRA Health Sciences Inc. (NASD: PRAH) in the S&P MidCap 400 effective p...
Through this strategic partnership, the network aims to reach more than 25,000 physicians and 40 million patients, accelerating trial recruitment and enrollment efforts and expanding patients’ access to clinical research Veradigm®, a leading provider of healthcar...
Strengthening Board of Directors with Expertise in Innovative Product Launches NEW YORK, May 26, 2021 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiat...